RecruitingN/Aketamine

Working Mechanisms and Effectiveness of IV Ketamine-assisted Psychotherapy on Depression in TRD Clients

Sponsored by Senz

NCT ID
NCT07706478
Target Enrollment
120 participants
Start Date
2025-06-01
Est. Completion
2033-01

About This Study

Ketamine-Assisted Psychotherapy (KAP) is an innovative treatment that combines intravenous ketamine with psychotherapy in a carefully monitored clinical setting. At Senz, this treatment is being evaluated in an open-label clinical trial for individuals with persistent depression who have not responded sufficiently to previous treatments. The combination of ketamine, psychological support, and integration sessions aims to promote emotional processing, psychological flexibility, and lasting therapeutic change.

Conditions Studied

Treatment Resistant Depression

Eligibility

Age:18 Years - 70 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Adults (18 years and older)
* TRD
* A MADRS score above the established clinical cut-off, indicating clinically significant depressive symptoms
* Insufficient response to at least two adequate antidepressant treatment trials and one evidence-based psychotherapy, or failure to achieve adequate improvement following at least three consecutive treatment steps in accordance with the Dutch Multidisciplinary Guideline for Depression

Exclusion Criteria:

* Current substance use disorder or recent illicit drug use
* Substance use disorder not in remission for at least 3 months
* Inability to abstain from alcohol for 24 hours before and after treatment
* Acute suicidality
* Current or past psychotic disorder
* Significant neurological disorders (e.g., epilepsy, elevated intracranial pressure)
* Uncontrolled hypertension or medical conditions associated with increased cardiovascular or cerebrovascular risk (e.g., aneurysms, recent myocardial infarction or intracerebral hemorrhage)
* Significant bladder disease (e.g., cystitis)
* Severe hepatic impairment
* Pregnancy, breastfeeding, or ongoing IVF treatment
* Extreme underweight or obesity where treatment is deemed medically unsafe Inability to arrange an accompanying adult for transport and support after treatment

Study Locations (1)

SENZ
Doorn, Utrecht, Netherlands

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

Rutger Engels, dr
CONTACT
+31 343 235300r.engels@senzggz.nl
karlijn kindt, dr
CONTACT
+31343 235300k.kindt@senzggz.nl
View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source